Press release
Cervical Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
Cervical Cancer Pipeline
Key Takeaways from the Cervical Cancer Pipeline Report
• DelveInsight's Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Cervical Cancer treatment.
• The leading companies are working in the Cervical Cancer Market include Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, Akeso Biopharma, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Celgene/MedImmune, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Genentech, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, and others.
• Promising Cervical Cancer Pipeline Therapies in the various stages of development include M7824, Carboplatin, Paclitaxel, Balstilimab, Zalifrelimab, tisotumab vedotin, Topotecan, Vinorelbine, GX-188E, Keytruda, and others.
• October 2023: Regeneron Pharmaceuticals announced a study of Phase 2 Clinical trials for Cemiplimab and ISA101b. The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
• October 2023: Seagen Inc. announced a study of Phase 1 & 2 clinical trials for Bevacizumab and Pembrolizumab. This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
Request a sample and discover the recent advances in Cervical Cancer Treatment Drugs @ Cervical Cancer Pipeline Report- https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Cervical Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Cervical Cancer NDA approvals (if any), and product development activities comprising the technology, Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Cervical Cancer Overview
Cervical cancer remains the fourth most common cancer in developing countries. It develops in a woman's cervix (the entrance to the uterus from the vagina) and happens when the cells on your cervix begin to change to precancerous cells. Not all precancerous cells will turn to cancer, but finding these problematic cells and treating them before they can change is critical to preventing cervical cancer.
Find out more about Cervical Cancer Therapeutics Assessment @ Cervical Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cervical Cancer Emerging Drugs Profile
• Axalimogene filolisbac: Advaxis
• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
• AK104: Akeso
• Durvalumab: AstraZeneca
• HLX10: Shanghai Henlius Biotech
Cervical Cancer Pipeline Therapeutics Assessment
There are approx. 70+ key companies which are developing the Cervical Cancer therapies. The Cervical Cancer companies which have their Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, Advaxis.
Cervical Cancer Pipeline Segmentation
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Learn more about the emerging Cervical Cancer Pipeline Therapies @ Cervical Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Cervical Cancer Pipeline Report
• Coverage- Global
• Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cervical Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cervical Cancer Companies- Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, Akeso Biopharma, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Celgene/MedImmune, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Genentech, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, and others.
• Cervical Cancer Pipeline Therapies- M7824, Carboplatin, Paclitaxel, Balstilimab, Zalifrelimab, tisotumab vedotin, Topotecan, Vinorelbine, GX-188E, Keytruda, and others.
Dive deep into rich insights for new drugs for Cervical Cancer Treatment, Visit @ Cervical Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Cervical Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cervical Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Axalimogene filolisbac : Advaxis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. QL 1604: Qilu Pharmaceutical
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. NP 137: Netris Pharma
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RTX 321: Rubius Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cervical Cancer Key Companies
21. Cervical Cancer Key Products
22. Cervical Cancer- Unmet Needs
23. Cervical Cancer- Market Drivers and Barriers
24. Cervical Cancer- Future Perspectives and Conclusion
25. Cervical Cancer Analyst Views
26. Cervical Cancer Key Companies
27. Appendix
For further information on the Cervical Cancer Pipeline therapeutics, reach out to Cervical Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cervical Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated) here
News-ID: 3256399 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
